Conflicts of interest: No funding sources.
Solar urticaria unresponsive to intravenous immunoglobulins
Article first published online: 4 JAN 2011
© 2011 John Wiley & Sons A/S
Photodermatology, Photoimmunology & Photomedicine
Volume 27, Issue 1, pages 53–54, February 2011
How to Cite
Llamas-Velasco, M., Argila, D. D., Eguren, C., García-Martin, P., Ibañes, S. and García-Diez, A. (2011), Solar urticaria unresponsive to intravenous immunoglobulins. Photodermatology, Photoimmunology & Photomedicine, 27: 53–54. doi: 10.1111/j.1600-0781.2010.00553.x
- Issue published online: 4 JAN 2011
- Article first published online: 4 JAN 2011
- Accepted for publication: 18 August 2010
- intravenous immunoglobulins;
- solar urticaria
The treatment of solar urticaria (SU) can be difficult. Only a few cases of SU have been treated with intravenous immunoglobulins (IVIg) (as monotherapy or combined with phototherapy), with reported fast and durable increase of solar exposure tolerance. A 61-year-old female with severe UVB- and UVA-induced SU and a 62-year-old female with severe UVA and visible light-induced SU were both treated with a single course of IVIg (total dose of 2 g/kg), infused over 3 days. Phototest, performed 3 months after the treatment, showed only a slight minimal urticating dose improvement, and both patients reported just a moderate and ‘transient’ subjective improvement. Our patient's poorer response, compared with previous reports, may be due to differences in IVIg's treatment schedules, which are reviewed.